Centauri Therapeutics

Executive Summary

Centauri Therapeutics is a UK-based immunotherapy company founded in 2015 and headquartered in Oxford. The company leverages its proprietary Alphamer technology platform to develop novel therapeutics for life-threatening infectious diseases and oncology. Alphamers are designed to redirect pre-existing antibodies in patients to target and eliminate disease-causing agents, offering a unique approach to harnessing the immune system. Centauri focuses on vulnerable patient populations with high unmet medical needs, such as those with antibiotic-resistant infections or hard-to-treat cancers. While the company remains private with limited publicly disclosed financial or pipeline details, its platform has potential across multiple indications. The Alphamer technology could enable rapid development of therapies without the need for de novo antibody generation, potentially reducing costs and development timelines. Centauri's approach is particularly relevant in the context of rising antimicrobial resistance and the need for novel cancer immunotherapies. The company's early-stage status and lack of disclosed clinical data present both opportunity and risk for investors.

Upcoming Catalysts (preview)

• Q2 2026Lead Program IND Filing or Phase I Initiation40% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data70% success
• Q4 2026Series B or Strategic Partnership Announcement50% success